Revcovi
Chemical Name | elapegademase-lvlr |
Dosage Form | Injection (intramuscular; 0.2 mg/kg, 0.4 mg/kg) |
Drug Class | Oligonucleotides |
System | Blood |
Company | Leadiant Biosciences, Inc. |
Approval Year | 2018 |
Indication
- To treat adenosine deaminase severe combined immunity deficiency.